San Diego-dependent Viking Therapeutics marked by itself as a significant competitor from the weight loss drug market place in February soon after revealing promising details from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection As well as in